[Back to Issue 2 ToC] [Back to Journal Contents] [Back to Biochemistry (Moscow) Home page]

REVIEW: Problems of Glioblastoma Multiforme Drug Resistance

A. A. Stavrovskaya, S. S. Shushanov, and E. Yu. Rybalkina*

Blokhin Russian Cancer Research Center, 115478 Moscow, Russia; fax: +7 (499) 323-5777; E-mail: Kate_Rybalkina@mail.ru

* To whom correspondence should be addressed.

Received May 19, 2015; Revision received June 24, 2015
Glioblastoma multiforme (GBL) is the most common and aggressive brain neoplasm. A standard therapeutic approach for GBL involves combination therapy consisting of surgery, radiotherapy, and chemotherapy. The latter is based on temozolomide (TMZ). However, even by applying such a radical treatment strategy, the mean patient survival time is only 14.6 months. Here we review the molecular mechanisms underlying the resistance of GBL cells to TMZ including genetic and epigenetic mechanisms. Present data regarding a role for genes and proteins MGMT, IDH1/2, YB-1, MELK, MVP/LRP, MDR1 (ABCB1), and genes encoding other ABC transporters as well as Akt3 kinase in developing resistance of GBL to TMZ are discussed. Some epigenetic regulators of resistance to TMZ such as microRNA and EZH2 are reviewed.
KEY WORDS: glioblastoma, temozolomide, drug resistance, YB-1 gene, microRNA

DOI: 10.1134/S0006297916020036